Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Factors in Patient Empowerment: A Survey of an Online Patient Research Network.
Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
Rare onset symptoms in multiple sclerosis.
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Voiding Dysfunction in Multiple Sclerosis.
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need.
Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11)
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
Glial cells as drug targets: What does it take?
Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
Intrathecal interferon reduces exacerbations of multiple sclerosis.
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
Differential transcriptional response profiles in human myeloid cell populations.
The "poison chair" treatment for multiple sclerosis.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients
Dimethyl fumarate induces necroptosis in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway.
CinnoVex home page
Policy: NIH to balance sex in cell and animal studies.
Timing of birth and risk of multiple sclerosis: population based study.

Pages